Not a Boring Conference - JP Morgan 2026 Healthcare Conference Gives Hope
JPM 2026 Healthcare Conference Debrief
Conferences are boring. I get it. Even folks attending a conference in person are usually only excited for a select few talks and presentations. So, how in the world could a newsletter reporting on a conference be interesting to read? It sounds like the kind of content that you close before finishing the first paragraph. Am I setting myself up for failure by even writing an article on a conference? I think this is worth the experiment. Why? Stick with me and find out.
The J.P. Morgan Healthcare Conference (JPM) is an annual conference that takes place at the beginning of each year. JPM isn’t the typical stuffy corporate conference where empty suits wearing laminated lanyard badges make small talk in a hotel lobby while drinking cheap, stale coffee in a paper cup. Things that matter happen here. It’s billions of capital allocation compressed into four days. This is where Pfizer announced a $10 billion bet on obesity drugs. Where a Chinese biotech nobody’s heard of signs a $5 billion deal with AbbVie. Where Eli Lilly and Nvidia announce they’re building a $1 billion AI lab to redesign drug discovery. Many of the major healthcare investment, M&A transaction, and strategic pivots for the next 12 months were either announced or negotiated in these San Francisco hotel suites.
The stakes this year were unusually high. Biotech has been bleeding since early 2021; venture funding is down 60% from the COVID high, IPO markets frozen for two years, public biotech indices cratered 40-70%. Companies have been in pure survival mode: slashing R&D budgets, killing early-stage programs, and executing mass layoffs. I’ve heard countless times anecdotally that this is the worst job market anyone can remember for biotech — very little hiring and hundreds of applications within a day of a position opening. The fundamental question walking into JPM 2026 was simple: is the bottom in, or are we still in free fall?
The answer matters because what happens in biotech doesn’t stay in biotech. These are the companies developing obesity drugs that could reshape public health and economy-wide productivity. The AI systems that might actually deliver on precision medicine promises. The gene therapies potentially curing diseases we’ve treated as chronic for decades. When biotech capital flows freeze, medical innovation stalls. When it thaws, we get therapeutic revolutions.
So what did JPM 2026 reveal? Three critical signals:
First: the industry has pivoted from survival to offense. Companies showed up with diversified pipelines, strong balance sheets, and aggressive execution timelines. The defensive crouch is over. Capital markets are reopening—IPO volume up 157%, M&A activity up 59%, venture funding recovering. Money is moving again.
Second: AI crossed the hype threshold into operational reality. Not PowerPoint decks about “AI strategy.” Actual billion-dollar infrastructure builds, agentic systems running clinical trials autonomously, measurable ROI from drug discovery acceleration. The conversation shifted from “what if” to “how much” and “how fast.”
Third: policy became the dominant risk variable. Trump administration healthcare policies, e.g., drug pricing agreements, FDA upheaval, $1 trillion Medicaid cuts, vaccine policy chaos, transformed from background noise into a significant strategic concerns. Companies can no longer treat the regulation landscape as stable and predictable in this context. It’s now a first-order business variable demanding continuous adaptation.
The detailed picture is more complex. GLP-1 obesity drugs are fragmenting into fierce competition across oral pills, injection frequencies, and patient segmentation strategies. Neuroscience investment is surging toward $83 billion annually, nearly matching immunology. Antibody-drug conjugates and radioligand therapies are becoming oncology’s next billion-dollar modalities. Health systems are bracing for financial catastrophe while private equity circles distressed assets.
What follows is the comprehensive breakdown: the deals that happened, the technologies gaining momentum, the capital flowing into specific therapeutic areas, and the strategic bets defining 2026. This is the intelligence driving where billions get deployed, which diseases get cured, and what the next decade of medicine looks like.
First, if you enjoy these posts, consider subscribing and becoming a part of our growing community!
Key Takeaways from JPM 2026
1. AI and Digital Health Take Center Stage.
Major players announced AI-driven collaborations (e.g. a $1 billion Lilly–Nvidia drug discovery lab) and new digital health initiatives, underscoring the conference’s tech-focused buzz. From clinical R&D to hospital operations, healthcare AI and data analytics were hailed as critical drivers of efficiency and innovation.
The Eli Lilly-Nvidia partnership establishes a joint innovation lab in South San Francisco to create a “continuous learning system” linking wet labs with computational dry labs (some of which we discussed in the 2025 Biotech Breakthroughs article). AI will assist researchers 24/7, improving experiments and model development. The facility is expected to become functional early 2026.
Anthropic announced Claude for Healthcare at JPM 2026, HIPAA-ready infrastructure for enterprise with native integration to medical and scientific databases. This follows Claude for Life Sciences launched in October 2025. Hippocratic AI acquired Grove AI to create a new life sciences division. Grove’s agentic AI for pharma R&D; and clinical trial operations will combine with Hippocratic’s patient-facing capabilities.
OpenEvidence is building “medical super-intelligence” through specialist models for oncology, neurology, and radiology rather than a single centralized model. Waystar launched agentic AI for revenue cycle management. The company processed 7.5 billion insurance transactions in 2025 and acquired Iodine Software in July 2025, which processes 1 in 3 clinical hospital discharges. Waystar projects its addressable market will expand from $20-25 billion to $55 billion by 2030 with AI.
2. Obesity Drugs and Metabolic Health Dominate Discussion.
The industry’s incretin-based weight-loss drug boom (GLP-1 receptor targeting peptides and beyond) was front and center. Eli Lilly’s soaring fortunes (first-ever $1 trillion pharma) and Novo Nordisk’s strategies (like a next-gen combo injection and direct-to-patient channels) underscored fierce competition in the anti-obesity market. Even new entrants like Pfizer touted ambitious plans after big acquisitions in this space.
Novo Nordisk’s Strategic Reset:
New CEO Mike Doustdar, installed mid-2025, acknowledged that 2025 was “difficult.” The company ceded US market leadership to Eli Lilly despite pioneering the GLP-1 obesity market. Novo launched oral Wegovy in January 2026 as the first FDA-approved oral GLP-1 for obesity in the US. Pricing: $149/month for 1.5mg and 4mg doses, up to $299/month for higher strengths.
The company is pursuing direct-to-consumer dominance through partnerships with Ro Health, Weight Watchers, and Costco. Novo relaunched its online pharmacy and reframed obesity as a “consumer business” rather than traditional chronic disease.Strategic refocus: pulling back from indications unrelated to diabetes and obesity. Novo and Lilly combined serve only 10-15 million of the estimated 100 million Americans with obesity. Pipeline differentiation centers on amylin biology. CagriSema (semaglutide + cagrilintide) demonstrated ~23% weight loss with only 3.7% discontinuation due to GI side effects.
Eli Lilly’s Dominance:
Lilly became the first pharmaceutical company ever to achieve a $1 trillion market
capitalization. CEO David Ricks projected 5-7% annual sales growth for the latter half of the decade. LillyDirect, the direct-to-consumer pharmacy platform, now serves over 1 million patients globally and is expanding internationally. Ricks described the platform as originally a “skunkworks” project that taught Lilly “profound” lessons about patient receptivity and demand for price transparency. Oral GLP-1 orforglipron awaits FDA decision in Q2 2026. Clinical trial design allowed greater flexibility than Novo’s oral Wegovy—no 30-minute fasting requirement and no restrictions on statin co-administration.
Pfizer’s $10 Billion Gamble:
Pfizer’s Metsera acquisition (announced September 2025, closed November 2025) followed a bruising bidding war with Novo Nordisk. Final valuation: ~$7 billion upfront + $20.65/share CVR for up to ~$10 billion total. CEO Albert Bourla explained why Metsera justifies this extraordinary valuation. The Metsera portfolio includes MET-097i (ultra-long-acting injectable GLP-1 for monthly dosing, currently in Phase IIb) and MET-233i (ultra-long-acting GLP-1 + amylin combination). Pfizer also separately acquired YP05002 (oral GLP-1) from YaoPharma. Pfizer initiated the first of 10 planned Phase III studies for MET-097i weeks after closing the acquisition—ahead of Metsera’s original Q1 2026 timeline. All remaining nine trials will start in 2026, targeting a 2028 launch to offset Pfizer’s patent cliff. Bourla projects the obesity market at $150 billion by 2030, driven substantially by cash-pay markets. He noted that when Pfizer launched Viagra, the company was “surprised how it was the first medicine that people were willing to pay out of pocket to get the medicine, irrelevant if it was covered or not by the system.” Pfizer is reportedly seeking a Commissioner’s National Priority Voucher (launched June 2025) to reduce review time from 10-12 months to 1-2 months.
3. Shift from Mega-Mergers to Targeted Deals.
While few blockbuster M&As dropped during JPM, a flurry of licensing partnerships filled the void. Examples include AbbVie’s $650 million licensing of a Chinese cancer drug (deal valued up to $5.6 billion), Novartis’s radioligand deal in China, and AstraZeneca’s purchase of an AI startup. These focused deals reflect an emphasis on plugging pipeline gaps over pursuing huge acquisitions.
Total announced deals during the conference: approximately $8.3 billion.
AbbVie-RemeGen Transaction: AbbVie’s $5.6 billion licensing agreement with Yantai-based RemeGen for RC148: $650 million upfront and up to $4.95 billion in development, regulatory, and commercial milestones, plus tiered double-digit royalties on ex-China sales. RC148 is a PD-1/VEGF bispecific antibody for advanced solid tumors including NSCLC and colorectal cancer. RemeGen is advancing Phase 2 trials in China. FDA approved Phase 2 trial initiation in August 2025. China’s NMPA granted breakthrough designation for RC148 combined with docetaxel as second-line therapy for NSCLC.
AbbVie aims to integrate RC148 with its ADC portfolio, particularly telisotuzumab adizutecan (Emrelis), approved May 2025 for c-Met overexpressing NSCLC. Early clinical data show antitumor activity when RC148 combines with ADCs. AbbVie also secured an option agreement with Zejing Biopharmaceutical for alveltamig (ZG006), a DLL3-targeting trispecific T-cell engager: $100 million upfront, $60 million more if option exercised, and up to $1.07 billion in total milestones. Alveltamig targets small cell lung cancer, competing with Amgen’s recently approved Imdelltra.
Other Major PD-1/VEGF Transactions:
• Pfizer + 3SBio: SSGJ-707 for up to $6 billion (2025)
• MSD + LaNova: LM-299 for $3.3 billion (2023)
• Summit Pharma + Akeso: ivonescimab for $5 billion (2022)
• Summit filed BLA with FDA on January 12, 2026 for US approval
• Could be first PD-1/VEGF bispecific approved in US
• Beat Keytruda on PFS in Chinese NSCLC patients
• BioNTech + Biotheus: BNT327 for $950 million, then licensed to BMS for $11 billion
Every major PD-1/VEGF licensing transaction involves China-developed assets. Industry leaders warned of a “Sputnik moment” and urged policymakers to support domestic innovation or risk losing leadership.
Novartis Deals:
Novartis secured licensing rights from SciNeuro Pharmaceuticals for Alzheimer’s antibody treatments (~$1.7 billion) and advanced radioligand therapy deals in China.
Johnson & Johnson-Intra-Cellular Therapies:
J&J;’s $14.6 billion acquisition (announced January 13, 2025; closed April 2, 2025) represents the largest biotech acquisition since early 2023 and the fourth multi-billion dollar neuroscience deal in recent months (after Karuna, Cerevel, Longboard). Key asset: Caplyta (lumateperone) for schizophrenia and depressive episodes in bipolar I/II disorder. Intra-Cellular filed supplemental NDA in December 2024 for major depressive disorder adjunctive therapy, potentially expanding addressable market dramatically. Pipeline includes ITI-1284 in Phase 2 for generalized anxiety disorder and Alzheimer’s disease-related psychosis. J&J; expects $0.7 billion incremental 2025 sales, with EPS dilution $0.25 (improved from original $0.30-0.35 estimate). J&J; also acquired Ambrx for nearly $2 billion in 2024 for ADC technology platform.
4. Robust Pipelines and New Launches Fuel Optimism.
Pharma CEOs used JPM to reassure investors about growth plans post-patent-cliffs. Companies like J&J (dozen launches by 2030), Novartis (12 pivotal readouts by 2027), Merck ($70 billion 2035 sales target), and GSK (15 blockbuster launches by 2031) highlighted rich late-stage pipelines. The message: rigorous R&D execution and pipeline diversification will sustain long-term growth.
5. Investor Sentiment: Cautious but Improving.
The biotech sector’s prolonged downturn showed signs of easing. A Q4 surge in venture funding and increased deal activity in late 2025 contributed to a more upbeat JPM. Attendees noted a “much busier than usual” atmosphere even without big buyouts. Overall, fundamentals appeared stronger, bringing a “sense of positivity and stability” not seen in recent years.
IPO Market Reopening: 2025 saw only 11 biotech IPOs price—lowest since at least 2018. However, most trade above offering prices, with Sionna Therapeutics and Maze Therapeutics more than doubling in value. This success rate signals investor selectivity returning. Investment bank projections suggest up to 20 biotech IPOs could price in 2026 if market conditions remain favorable. The pipeline consists primarily of mid-to-late-stage companieswith prior crossover funding, though a handful of preclinical companies with prominent investor backing might also IPO.
Conference Metrics: Over 8,000 attendees. 500+ companies presenting. Approximately $92 million economic impact for San Francisco. 150+ health systems in attendance (record number).
6. Policy and Regulatory Undercurrents.
Regulatory shifts loomed in many discussions. Pharma execs acknowledged the Inflation Reduction Act’s drug price controls – AbbVie noted an IRA hit even as new products offset Humira’s decline. Calls for PBM reforms to reduce patient costs were echoed. Industry leaders warned of a “Sputnik moment” as China’s rapid biotech rise spurs U.S. policymakers to support innovation or risk losing leadership. Meanwhile, the advent of HIPAA-compliant medical AI (e.g. ChatGPT Health and Claude for Healthcare) highlighted regulators’ next frontier.
7. Hospital Systems and Health Tech Trends.
Large health systems showcased post-merger integration gains and cost efficiencies. For example, Advocate Health reported $1.5 billion in savings since its mega-merger, alongside quality improvements. Digital health and medtech firms also had the spotlight – from wearable tech (e.g. Oura’s growth) to AI in care delivery (startups like OpenEvidence, and Waystar’s “agentic AI” for hospital billing). These trends underscored that tech-enabled care models and operational innovation remain investment priorities.
8. Additional Notable Developments.
Antibody-Drug Conjugates and Radioligand Therapies: Emerging as oncology’s next billion-dollar modalities. AbbVie’s Emrelis (telisotuzumab adizutecan) approved May 2025 for c-Met overexpressing NSCLC. Integration with PD-1/VEGF bispecifics in combination regimens. Novartis advancing radioligand deals in China for novel targets.
Direct-to-Consumer Pharmaceutical Shift: LillyDirect serves 1 million+ patients globally. Novo’s partnership network with Ro Health, Weight Watchers, Costco. Cash-pay markets becoming primary channel for lifestyle/wellness drugs. Ricks compared LillyDirect’s strategic value to Pfizer’s out-of-pocket market penetration with Viagra.
Conference Economics: Approximately $8.3 billion in deals announced during or immediately surrounding the conference. Venue: Westin St. Francis Hotel and surrounding San Francisco locations.
These newsletters take significant effort to put together and are totally for the reader’s benefit. If you find these explorations valuable, there are multiple ways to show your support:
Engage: Like or comment on posts to join the conversation.
Subscribe: Never miss an update by subscribing to the Substack.
Share: Help spread the word by sharing posts with friends directly or on social media.
I resonate with what you wrote. Conferences are often tedious. Your analysis of JPM's unique impact is insightful. The magnitude of capital allocation discussed is significant. The Eli Lilly and Nvidia AI lab announcement truely highlights critical future direction. This was a valuable read.
The Biotech Breakthroughs article seemed to be a foreshadow of the conference themes.